Annotation Detail
Information
- Associated Genes
- EGFR
- Associated Variants
-
EGFR EXPRESSION
EGFR EXPRESSION - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Double blind Phase II clinical trial found an objective response rate of 18.4% and 19% for two groups of patients treated with 250mg/d and 500mg/d respectively. The disease control rate was found to be 54.4% and 51.4% for the two groups.
- Variant Origin
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/4877
- Gene URL
- https://civic.genome.wustl.edu/links/genes/19
- Variant URL
- https://civic.genome.wustl.edu/links/variants/354
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Gefitinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 12748244
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Gefitinib | Sensitivity | true |